OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 41 - 50 of 695 studies

Cardiovascular

Evaluation of a Novel Diagnostic Test for Calcium Release Deficiency Syndrome

Millions of people suffer due to cardiac arrest every year and in many cases, the cause of the cardiac arrest is related to a disorder of the electrical activity of the heart. Calcium Release Deficiency Syndrome (CRDS) is a recently discovered electrical heart disorder that develops due to a genetic change in the RyR2 gene resulting in the low activity of RyR2 protein. Currently, CRDS needs genetic testing to be diagnosed and then the identified RyR2 genetic change needs to ...

GO TO STUDY Go

Neurological

Open Network for Frontotemporal dementia Inflammation REsearch (ON-FIRE)

There are many types of dementia. This research studies the family of illnesses known as Frontotemporal type of dementia. This devastating group of illnesses change behaviour, language, and movement. Frontotemporal dementia often affects younger adults and runs in families. There is long running inflammation in the brain with Frontotemporal dementia – suggesting that anti-inflammatory treatments might slow or prevent decline. However, no two people are the same in their symptoms, or in what drives inflammation. For example, genetics, lifestyle, ethnicity ...

GO TO STUDY Go

Metabolic and Endocrine

UK Islet Autoantibody Registry (UKIAb)

We aim to establish a registry of children young people and adults who are IAb positive. We will use the registry to address the following research questions: 1. What is the lived experience of being IAb positive,or having a child who is IAb positive? 2. What are IAb positive individuals’ and their families’ information and support needs? 3. What are the frequency and risk factors associated with clinical outcomes,including progression to Stage 3 T1D in a UK cohort 4. How does the UK IAb positive cohort compare ...

GO TO STUDY Go

Blood

A comparative observational study to evaluate the safety and effectiveness of Xromi® (hydroxycarbamide oral solution 100mg/ml) for the prevention of vaso-occlusive complications of sickle cell disease in children under 2 years of age.

We are conducting a study to gather more information on the safety and effectiveness of Xromi (hydroxyurea), a liquid medicine licensed to treat sickle cell disease (SCD) in children from 9 months of age. We aim to understand its safety profile and efficacy in preventing serious SCD complications (e.g., pain crises, acute chest syndromes, stroke) in children under 2 years when used in standard care. We will compare medical information collected during routine clinical appointments of children under 2 years who ...

GO TO STUDY Go

Respiratory

Exacerbation Prevention in chronic obstructive pulmonary disease (COPD) – obstructive sleep apnoea (OSA) overlap syndrome: The clinical and health economic impact of treating patients with COPD-OSA overlap syndrome and a high risk of future exacerbations with positive airway pressure therapy (PAP) a multicentre randomised controlled trial

Patients with chronic obstructive pulmonary disease-obstructive sleep apnoea (COPD-OSA) overlap syndrome have higher rates of COPD exacerbations compared to patients with similar severity COPD without OSA. It is currently not known whether treating OSA in those with COPD-OSA overlap reduces exacerbation rates. COPD exacerbations are characterised by acute transient worsening of symptoms such as dyspnoea, sputum production, sputum purulence and cough which are above the normal day to day variation in symptom burden and are usually associated with escalation of ...

GO TO STUDY Go

Neurological

An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod PH20 SC in Participants From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis

The purpose of this study is to measure the PK, PD, safety, tolerability, and immunogenicity of efgartigimod PH20 SC in pediatric participants with gMG aged 2 to < 18 years. The primary goal is to confirm an appropriate dose of efgartigimod PH20 SC for pediatric patients using PK and PD results from this study. Participants will receive 4 once-weekly injections of efgartigimod PH20 SC and will be monitored for safety until the end of the study. At the end of ...

GO TO STUDY Go

Reproductive health and childbirth

Cooling in Mild Encephalopathy (COMET) trial

Despite the lack of evidence on safety or efficacy, many clinicians offer whole body therapeutic hypothermia to infants with mild hypoxic ischaemic encephalopathy, and even to those without any encephalopathy. Such a wide variation in clinical practice within the NHS not only leads to poorer outcomes and may harm infants who would have otherwise done well, but masks improvements in obstetric care and increase litigations. The COMET trial will establish the safety and efficacy of whole-body hypothermia for mild hypoxic ischaemic ...

GO TO STUDY Go

Blood Injuries and accidents

A Randomised Trial of Timing to Restart Direct Oral Anticoagulants after Traumatic Intracranial Haemorrhage

The main purpose of the trial is to determine when the most beneficial time for people to start or restart a DOAC after their head injury is. People will be asked to start the medication either 1 week or 4 weeks after their head injury. This will be randomly assigned by a computer. They will then be followed closely for 12 weeks and any major bleeding events or a blood clots (thrombotic events) such as a stroke or heart attack ...

GO TO STUDY Go

Cardiovascular

REdo Transcatheter Aortic VALVE Implantation for the management of Transcatheter Aortic Valve Failure: REVALVE

Transcatheter aortic valve implantation (TAVI) is a key-hole technique to replace a faulty (narrowed and/or leaking) aortic heart valve. The replacement aortic valve is delivered to the heart through tubes inserted in a main artery (usually the artery in the groin). Over the past 15 years TAVI has rapidly grown and has taken over from open-heart surgery (surgical aortic valve replacement (SAVR)) to become the most commonly used technique for aortic heart valve replacement. Although TAVI is a safe and effective ...

GO TO STUDY Go

Oral and Gastrointestinal

A PrOspective RandoMIsed Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults with CROHN’s Disease: OMICROHN (OMICROHN)

This study will test if a new software program called EpiPredict can predict which biologic therapy might work best for treating Crohn’s disease (CD). This study will include about 378 participants from 6 countries in Europe, and about 98 participants in the United Kingdom (UK). EpiPredict will predict how well two biologics for CD (vedolizumab and ustekinumab) will work. Both vedolizumab and ustekinumab are approved for use in people with CD as part of their usual care. This study is testing if ...

GO TO STUDY Go